中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
2025.11.07
Haihe Biopharma's innovative drug PARP1 inhibitor has obtained clinical trial approval in China
Today, Haihe Biopharma (Haihe), announced that the companys self-developed selective PARP1 inhibitor (R&D code: HH10...
2025.10.16
Haihe Biopharma Enters Into Exclusive License Agreement with Taiho Pharma for PI3Kα Inhibitor Risovalisib (CYH33)
Haihe Biopharma Co., Ltd. (hereinafter “Haihe”) and Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) (“HaiHe”)...
Press Release
2022.02.18
Haihe Biopharma Announces NDA acceptance in China for MET inhibitor Glumetinib (SCC244)
2022.01.26
U.S. FDA Grants Orphan Drug Designation to Haihe Biopharma’s Glumetinib for Treatment of NSCLC with MET Genomic Aberration
2020.11.09
Haihe Biopharma and Noventi Pharma Reached Collaboration for Innovative Antibiotics
2020.10.27
Haihe Biopharma and 3DMed Reached Collaboration for Innovative Analgesics
2020.07.27
Haihe Biopharma Closed ￥1.20 Billion Series B Financing, Accelerating Global Development Efforts
2020.07.09
Haihe Biopharma obtains the IND Approval from NMPA for its innovative EZH1/2 dual inhibitor
2020.05.22
Haihe Biopharma obtains the IND Approval from FDA for its innovative PI3Ka inhibitor
2020.05.07
Haihe Biopharma obtains the IND Approval from FDA for its innovative IDH1 inhibitor
3
4
5
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
